APPLIED MOLECULAR TRANSPORT news, videos and press releases
For more news please use our advanced search feature.
APPLIED MOLECULAR TRANSPORT - More news...
APPLIED MOLECULAR TRANSPORT - More news...
- Applied Molecular Transport Reports Third Quarter 2023 Financial Results
- Applied Molecular Transport Reports Second Quarter 2023 Financial Results
- Applied Molecular Transport Reports First Quarter 2023 Financial Results
- Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives
- Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress
- Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
- Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
- Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Applied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
- Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
- Applied Molecular Transport to Present at Upcoming June Investor Conferences
- Applied Molecular Transport Provides Strategy Update
- Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update
- Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference
- Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
- Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
- Applied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight into Company’s Proprietary Technology Platform
- Applied Molecular Transport Appoints Charlene Banard to its Board of Directors
- Applied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory Affairs
- Applied Molecular Transport Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Applied Molecular Transport to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference
- Applied Molecular Transport Announces Board Appointments
- Applied Molecular Transport to Present at Virtual Jefferies London Healthcare Conference
- Applied Molecular Transport Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Applied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021
- Applied Molecular Transport Announces Upcoming Investor Events in September and October
- Applied Molecular Transport Appoints Holly Schachner, M.D. to its Board of Directors
- Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update
